SEC Form 4 · accession 0001780660-26-000017

Adaptive Biotechnologies Corp · ADPT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Francis Lo

Officer — Chief People Officer

Period of report

Jul 1, 2026

Accepted (ET)

Jul 6, 2026 · 7:19 pm EDT

Rule 10b5-1 plan

yes — trade under a plan

Issuer CIK

0001478320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Jul 1, 2026	M	3,500	$7.80	A	254,434	D
Common Stock	Jul 1, 2026	M	3,300	$12.14	A	257,734	D
Common Stock	Jul 1, 2026	M	12,206	$8.46	A	269,940	D
Common Stock	Jul 1, 2026	M	4,688	$3.99	A	274,628	D
Common Stock	Jul 1, 2026	M	14,064	$8.12	A	288,692	D
Common Stock^F2	Jul 1, 2026	S	8,743	$22.18	D	279,949	D
Common Stock^F3	Jul 1, 2026	S	42,261	$22.50	D	237,688	D
Common Stock	Jul 2, 2026	M	12,626	$7.80	A	250,314	D
Common Stock	Jul 2, 2026	M	12,600	$12.14	A	262,914	D
Common Stock	Jul 2, 2026	M	12,637	$8.46	A	275,551	D
Common Stock^F4	Jul 2, 2026	S	44,838	$22.59	D	230,713	D
Common Stock	holding	—	—		—	2,500	I	By You Jin Lee (spouse)

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F5	$7.80	Jul 1, 2026	M	3,500	D	—	May 6, 2029	Common Stock	3,500	72,000	D
Stock Option (right to buy)^F5	$12.14	Jul 1, 2026	M	3,300	D	—	Mar 4, 2032	Common Stock	3,300	168,523	D
Stock Option (right to buy)^F6	$8.46	Jul 1, 2026	M	12,206	D	—	Mar 6, 2033	Common Stock	12,206	72,859	D
Stock Option (right to buy)^F7	$3.99	Jul 1, 2026	M	4,688	D	—	Mar 4, 2034	Common Stock	4,688	81,265	D
Stock Option (right to buy)^F8	$8.12	Jul 1, 2026	M	14,064	D	—	Mar 4, 2035	Common Stock	14,064	126,584	D
Stock Option (right to buy)^F5	$7.80	Jul 2, 2026	M	12,626	D	—	May 6, 2029	Common Stock	12,626	59,374	D
Stock Option (right to buy)^F5	$12.14	Jul 2, 2026	M	12,600	D	—	Mar 4, 2032	Common Stock	12,600	155,923	D
Stock Option (right to buy)^F6	$8.46	Jul 2, 2026	M	12,637	D	—	Mar 6, 2033	Common Stock	12,637	60,222	D

Explanation of responses

F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.48 to $22.47, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.49 to $22.54, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.49 to $22.79, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5The option is fully vested and exercisable.
F6The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
F7The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
F8The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.